Login to Your Account



FDA Fast Tracks Alnylam RNAi Drug; Firm Launches Phase III

By Catherine Shaffer
Staff Writer

Monday, November 11, 2013
Alnylam Pharmaceuticals Inc. received coveted fast-track designation for its RNAi therapeutic, patisiran, to accelerate its development for treatment of transthyretin (TTR)-familial amyloid polyneuropathy (FAP). The company recently reported positive Phase II results for the product, and has begun a Phase III program.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription